H. C. Wainwright & Co. logo

H. C. Wainwright & Co.

North America, New York, United States, New York

Description

H.C. Wainwright & Co. blends traditional values with innovative services, operating with integrity and offering leading-edge investment.

Investor Profile

H. C. Wainwright & Co. has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (100%)

Country Focus

  • United States (50%)
  • Israel (50%)

Industry Focus

  • Biotechnology
  • Health Care
  • Genetics
  • Manufacturing
  • Medical Device
  • Medical
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does H. C. Wainwright & Co. frequently co-invest with?

ROTH Capital Partners
North America, California, United States, Newport Beach
Co-Investments: 1
M&
North America, New York, United States, New York
Co-Investments: 1
Jefferies
North America, New York, United States, New York
Co-Investments: 1
Nomura
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
FBR & Co
North America, Virginia, United States, Arlington
Co-Investments: 1
RBC Capital Markets
North America, New York, United States, Albany
Co-Investments: 1
Cantor Fitzgerald
North America, New York, United States, New York
Co-Investments: 1
Maxim Group
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by H. C. Wainwright & Co.?

Abeona Therapeutics

New York, New York, United States

Abeona Therapeutics develops gene therapy-based potential cures for Sanfilippo syndrome types A and B.

BiotechnologyGeneticsHealth CareManufacturingMedical Device
Post Ipo EquityOct 19, 2017
Amount Raised: $92,000,000
RedHill Biopharma

Tel Aviv, Tel Aviv, Israel

RedHill Biopharma specializes primarily in gastrointestinal and infectious diseases within the realm of specialty biopharmaceuticals.

BiotechnologyHealth CareMedicalPharmaceutical
Post Ipo EquityJul 20, 2015
Amount Raised: $40,000,000